Nicole Gina Lapuyade

US Patent:

20220306717, Sep 29, 2022

Filed:

Mar 16, 2022

Appl. No.:

17/696222

Inventors:

- South San Francisco CA, US
Nicole G. LAPUYADE - San Francisco CA, US
Hikmat Haizar ASSI - San Pablo CA, US
Madan M. PAIDHUNGAT - San Francisco CA, US
Dylan L. DANIEL - San Francisco CA, US
Erwan LE SCOLAN - San Francisco CA, US
Walter A. BOGDANOFF - Rio Vista CA, US
Na CAI - San Mateo CA, US
Hsin WANG - San Mateo CA, US
Alexey Yevgenyevich BEREZHNOY - Burlingame CA, US

Assignee:

CytomX Therapeutics, Inc. - South San Francisco CA

International Classification:

C07K 14/56
C07K 14/565
C07K 14/57

Abstract:

Provided herein are activatable cytokine constructs that include: (a) a first monomer construct comprising a first peptide mask (PM1), a third cleavable moiety (CM3), a first mature cytokine protein (CP1), a first cleavable moiety (CM1), and a first dimerization domain (DD1), wherein the CM1 is positioned between the CP1 and the DD1, and the CM3 is positioned between the PM1 and CP1; and (b) a second monomer construct comprising a second mature cytokine protein (CP2), a second cleavable moiety (CM2), and a second dimerization domain (DD2), where the CM2 is positioned between the CP2 and the DD2, where: the DD1 and the DD2 bind each other; and where the ACC is characterized by a reduction in at least one activity of the CP1 and/or CP2 as compared to a control level of the at least one activity of the CP1 and/or CP2.

US Patent:

20210317177, Oct 14, 2021

Filed:

Apr 9, 2021

Appl. No.:

17/227017

Inventors:

- South San Francisco CA, US
Nicole G. Lapuyade - San Francisco CA, US
Hikmat Haizar Assi - San Pablo CA, US
Madan M. Paidhungat - San Francisco CA, US
Dylan D. Daniel - San Francisco CA, US
Erwan Le Scolan - San Francisco CA, US
Walter A. Bogdanoff - Rio Vista CA, US
Na Cai - San Mateo CA, US
Hsin Wang - San Mateo CA, US

Assignee:

CytomX Therapeutics, Inc. - South San Francisco CA

International Classification:

C07K 14/56

Abstract:

Provided herein are activatable cytokine constructs that include: (a) a first monomer construct comprising a first mature cytokine protein (CP1), a first cleavable moiety (CM1), and a first dimerization domain (DD1), wherein the CM1 is positioned between the CP1 and the DD1; and (b) a second monomer construct comprising a second mature cytokine protein (CP2), a second cleavable moiety (CM2), and a second dimerization domain (DD2), where the CM2 is positioned between the CP2 and the DD2, where: the CM1 and the CM2 function as a substrate for a protease; the DD1 and the DD2 bind each other; and where the ACC is characterized by a reduction in at least one activity of the CP1 and/or CP2 as compared to a control level of the at least one activity of the CP1 and/or CP2.